Core Insights - The article highlights the significant breakthrough of Meizhong Jiahe (02453.HK) in the field of tumor precision diagnosis and treatment, particularly with the launch of its self-developed proton therapy vertical large language model [1][4] - The deployment of this model at Guangzhou Taihe Tumor Hospital marks a milestone in the intelligentization of tumor medical services, showcasing the company's strong technical capabilities and immense commercial potential [1][4] Company Developments - Meizhong Jiahe's subsidiary, Beijing Hexin Kang Technology Co., Ltd., established in 2015, focuses on improving medical services through artificial intelligence technology [1] - The proton large model is a pioneering achievement in the proton therapy vertical field, establishing industry technical standards and filling a gap in the market [1][3] Application and Impact - The proton large model has been successfully implemented at Guangzhou Taihe Tumor Hospital, which is the first clinical center in South China equipped with the Varian ProBeam proton radiation therapy system [2] - The model's training data is sourced from the hospital's clinical processes, ensuring accuracy and relevance, which enhances the efficiency of "human-machine collaboration" in treatment [2] Future Plans - The development plan for the proton large model extends beyond proton therapy, aiming to create an AI diagnostic matrix covering the entire lifecycle of tumor screening, diagnosis, treatment, and rehabilitation [3] - This approach allows Meizhong Jiahe to improve the efficiency and quality of its medical services while also enabling diverse collaborations with other medical institutions through technology licensing and remote diagnostic support [3] Market Position - As the first company in Hong Kong to engage in proton therapy, Meizhong Jiahe has established a strong competitive barrier in the tumor diagnosis and treatment sector [4] - The launch of the proton large model elevates the company's advantages, redefining industry standards and accelerating the intelligent transformation of the tumor medical industry [4]
质子大模型领航！美中嘉和（02453.HK）开启肿瘤诊疗智能新纪元